Skip to main content
OpenTrials
Completed

NCT Number: NCT05261191

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Study CP-MGD020-01 is a phase 1, open-label, dose-escalation, and multi-dose expansion study of MGD020 as a single agent or in combination with MGD014 in persons with HIV-1 (PWH) on antiretroviral therapy (ART). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of the study drugs. The study consists of 3 parts (Part 1A, Part 1B, and Part 2). The participant's standard of care ART regimen is continued throughout the study period.

MGD020 is a bispecific DART® molecule that binds CD3 and gp41 subunit of HIV-1 envelope. MGD014 is a bispecific DART® molecule that binds CD3 and gp120 subunit of HIV-1 envelope. These DART molecules redirect CD3+ T lymphocytes to kill HIV-1-infected CD4+ T cells.

Part 1A evaluates groups of participants given a single dose of MGD020. A 2-week safety period is observed prior to escalation to the next dose level. Dose escalation continues until either the maximum tolerated dose (MTD) or maximum administered dose (MAD) is determined.

Part 1B begins after the end of Part 1A. Part 1B evaluates groups of participants given a single dose of the MGD020 MTD or MAD from Part 1A and a fixed dose of of MGD014. The first group will be treated with a single dose of MGD020, at a dose determined to be one dose lower than the single-agent MTD/MAD from Part 1A, and a single 300 mcg/kg dose of MGD014. Dose escalation proceeds until either the MTD or MAD is determined.

Part 2 begins after the end of Part 1B. Part 2 is a multi-dose expansion group. Each participant will receive the MTD or MAD of MGD020 from Part 1B and a fixed dose of MGD014 from Part 1B, administered every 2 weeks (Q2W) for 3 combination doses over 4 weeks. Up to 6 participants may be enrolled in Part 2.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Human Immunodeficiency Virus I Infection Acquired Immunodeficiency Syndrome Blood-Borne Infections Communicable Diseases Genital Diseases HIV Infections Human Immunodeficiency Virus Type 1 Immune System Diseases Immunodeficiency Virus Type 1, Human Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Urogenital Diseases Virus Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Icahn School of Medicine at Mt. Sinai, New York, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged ≥ 18 years and ≤ 70 years of age and able to provide informed consent
  • HIV-1 infection documented by rapid HIV test or HIV enzyme or chemiluminescence immunoassay and confirmed by a different second test.
  • Plasma HIV-1 RNA viral load
  • < 50 copies/mL at 2 time points within 24 months prior to screening (1 time point within 12 months prior to screening), and
  • < 50 copies/mL at screening, and
  • Not ≥ 50 copies/mL on 2 consecutive time points within 24 months nor > 1000 copies/mL at any time within 6 months prior to screening
  • On continuous antiretroviral therapy (ART) for at least 24 months prior to screening and must continue ART throughout the study.
  • CD4 cell count > 350 cells/mm3 at screening
  • Acceptable laboratory values related to bone marrow, kidney and liver function.
  • Individuals of childbearing potential must agree to use highly effective forms of contraception throughout the study through 6 months after the last dose of MGD014.

Exclusion criteria

  • History of any HIV-1 vaccine or HIV-1 immunotherapy, except MGD014 or MGD020, within 6 months prior to screening.
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient.
  • Active viral, bacterial, or systemic fungal infection requiring intravenous antibiotic, antiviral, or antifungal treatment within 7 days prior to the initiation of study drug.
  • Active coronavirus disease 19 (COVID-19)/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • Participation in another investigational clinical research study within 60 days prior to screening.
  • History of virologic failure on an ART regimen containing FDA-approved HIV-1 entry inhibitors (maraviroc, enfuvirtide, and/or ibalizumab). Virologic failure is defined as a confirmed plasma HIV-1 RNA ≥ 150 copies/mL following assessment of drug adherence, repeat HIV-1 RNA testing with continued treatment, and/or resistance testing

Treatment and study plan

MGD020

Biological

MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

MGD014

Biological

MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.

Primary outcomes

  1. Number and Types of Adverse Events (AEs), Including Serious Adverse Events (SAEs), and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 Alone in Part 1A

    Time frame: Throughout the study, up to 43 days

    Observation of side effects determines the highest safe dose for further study

  2. Number and Types of AEs, Including SAEs, and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 and MGD014 in Part 1B.

    Time frame: Throughout the study, up to 43 days

    Observation of side effects determines the highest safe dose for further study

  3. Number and Types of AEs, Including SAEs, and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 and MGD014 in Part 2.

    Time frame: Throughout the study, up to 81 days.

    Observation of side effects determines the highest safe dose for further study

Secondary outcomes

  1. Mean Maximum Concentration of MGD020

    Time frame: Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2

    The highest concentration of MGD020 at the end of the infusion

  2. Mean Maximum Concentration of MGD014

    Time frame: Throughout the study, up to 43 days for Part 1B, and up to 78 days for Part 2

    The highest concentration of MGD014 at the end of the infusion (Cmax).

  3. Mean Time to Maximal Concentration of MGD020

    Time frame: Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2

    The amount of time required to get maximum concentration of MGD020

  4. Mean Time to Maximal Concentration of MGD014

    Time frame: Throughout the study, up to 43 days for Part 1B, and up to 78 days for Part 2

    The amount of time required to get maximum concentration of MGD014

  5. Mean Area Under the Concentration-time Curve (AUC) of MGD020

    Time frame: Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2

    Total body exposure to MGD020

  6. Mean AUC of MGD014

    Time frame: Throughout the study, up to 43 days for Parts 1B, and up to 78 days for Part 2

    Total body exposure to MGD014

  7. Mean Half-life of MGD020

    Time frame: Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2

    The amount of time needed for the body to clear half of the dose of MGD020

  8. Mean Half-life of MGD014

    Time frame: Throughout the study, up to 43 days for Parts 1B, and up to 78 days for Part 2

    The amount of time needed for the body to clear half of the dose of MGD014

  9. Mean Volume of Distribution at Steady State (Vss) of MGD020

    Time frame: Throughout the study, up to 78 days for Part 2

    This parameter measures how much of the drug remains in the bloodstream or is distributed to body tissues.

  10. Mean Volume of Distribution at Steady State of MGD014

    Time frame: Throughout the study, up to 78 days for Part 2

    This parameter measures how much of the drug remains in the bloodstream or is distributed to body tissues.

  11. Mean Clearance of MGD020

    Time frame: Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2

    Total body clearance of the drug from plasma of MGD020

  12. Mean Clearance of MGD014

    Time frame: Throughout the study, up to 43 days for Parts 1B, and up to 78 days for Part 2

    Total body clearance of the drug from plasma of MGD014

  13. Number of Participants With Elevations in Serum Cytokine Levels of IFN-γ, IL-2, IL-5, IL-6, IL-10, or TNF-α

    Time frame: Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2.

  14. Anti-drug Antibody Formation to MGD020

    Time frame: Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2

    Number of patients who develop antibodies against MDG020

  15. Anti-drug Antibody Formation to MGD014

    Time frame: Throughout the study, up to 43 days for Parts 1B, and up to 78 days for Part 2

    Number of patients who develop antibodies against MDG014

Sponsors and collaborators

Lead sponsor

MacroGenics

Industry

Collaborators

  • Department of Health and Human Services
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institutes of Health (NIH)

Registry information

Official study title

A Phase 1 Study of MGD020 as a Single Agent or in Combination With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Mar 2, 2022
Registry last updated
Mar 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.